HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women

被引:14
|
作者
Vogelvang, TE
Mijatovic, V
Kenemans, P
Teerlink, T
van der Mooren, MJ
机构
[1] Vrije Univ Amsterdam, Med Ctr, Dept Obstet & Gynecol, Project Aging Women, NL-1007 MB Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, ICaR, NL-1007 MB Amsterdam, Netherlands
关键词
HMR; 3339; raloxifene; menopause; lipids; lipoprotein(a); homocysteine; endothelin-1;
D O I
10.1016/j.fertnstert.2004.05.093
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To investigate the short-term effects of HMR 3339 in comparison with raloxifene and placebo on cardiovascular risk factors. Design: A multicenter, randomized, placebo-controlled, double-blind, dose-ranging study. Setting: Gynecologic outpatient department. Patient(s): One hundred eighteen healthy nonhysterectomized postmenopausal women. Intervention(s): Participants received daily placebo (n = 22), 2.5 mg of HMR 3339 (n = 25), 10 mg of HMR 3339 (n = 24), 50 mg of HMR 3339 (n = 24), or 60 mg of raloxifene (n = 23) for 12 weeks followed by a 2-week washout period. Main Outcome Measure(s): Blood concentrations of lipids measured at baseline, and after 2, 4, 8, 12, and 14 weeks, and of lipoprotein(a), homocysteine, and endothelin-1 measured at baseline, and after 4 and 12 weeks. Result(s): After 12 weeks of treatment with HMR 3339, compared with placebo, serum total cholesterol was reduced (10 mg of HMR 3339: -9.7%; 50 mg of HMR 3339: -15.2%), low-density lipoprotein (LDL)-cholesterol (10 mg of HMR 3339: -10.8%; 50 mg of HMR 3339: -24.2%) and plasma homocysteine concentrations (2.5 mg of HMR 3339: -3.9%; 10 mg of HMR 3339: -10.8%; 50 mg of HMR 3339: -13.8%), suggesting a dose-dependent effect of HMR 3339. These effects were already apparent after 2 weeks of treatment for total cholesterol and LDL-cholesterol, and after 4 weeks of treatment for homocysteine. After 12 weeks, raloxifene, compared with placebo, significantly decreased total cholesterol (-10.5%), LDL-cholesterol (-15.0%), and triglycerides (-16.9%), but not homocysteine. High-density lipoprotein-cholesterol, lipoprotein(a), and endothelin-1 showed no significant changes in any of the active treatment groups. Conclusion(s): HMR 3339 reduces total cholesterol, LDL-cholesterol, and homocysteine concentrations in postmenopausal women. (C) 2004 by American Society for Reproductive Medicine.
引用
收藏
页码:1540 / 1549
页数:10
相关论文
共 50 条
  • [1] Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal women
    Vogelvang, TE
    Mijatovic, V
    Kenemans, P
    Schalkwijk, CG
    van der Mooren, MJ
    AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (09): : 1205 - 1208
  • [2] Isoflavone supplementation reduces low-density lipoprotein cholesterol levels in postmenopausal women
    Yenny
    Pusparini
    UNIVERSA MEDICINA, 2013, 32 (03) : 197 - 207
  • [3] Sortilin Is a Novel Modulator of Low-Density Lipoprotein Cholesterol
    Strong, Alanna
    Musunuru, Kiran
    Frank-Kamenetsky, Maria
    Sachs, Katherine V.
    Li, Xiaoyu
    Li, Hui
    Lund-Katz, Sissel
    Phillips, Michael
    Wong, Jamie
    Cantley, Will
    Koteliansky, Victor
    Fitzgerald, Kevin
    Krauss, Ronald M.
    Kathiresan, Sekar
    Rader, Daniel J.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (11) : E188 - E188
  • [4] HMR 3339, a novel selective estrogen receptor modulator, reduces concentrations of procarboxypeptidase U, an inhibitor of fibrinolysis. A randomized, placebo-controlled study in postmenopausal women
    Vogelvang, TE
    Leurs, JR
    Mijatovic, V
    Willemse, J
    Van der Mooren, MJ
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (05) : 1090 - 1092
  • [5] Bone mineral density and low-density lipoprotein cholesterol in Saudi postmenopausal women
    Ardawi, MM
    Nasrat, HAN
    Bahksh, TM
    Maimany, AA
    Syamik, AY
    Milaat, WA
    BONE, 2005, 36 : S366 - S367
  • [6] Correlation between total homocysteine, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in the serum of patients with myocardial infarction
    Qujeq, D
    Omran, TS
    Hosini, L
    CLINICAL BIOCHEMISTRY, 2001, 34 (02) : 97 - 101
  • [7] Plasma low-density lipoprotein cholesterol and bone mass densitometry in postmenopausal women
    Poli, A
    Bruschi, F
    Cesana, B
    Rossi, M
    Paoletti, R
    Crosignani, PG
    OBSTETRICS AND GYNECOLOGY, 2003, 102 (05): : 922 - 926
  • [8] Genetics, Lifestyle, and Low-Density Lipoprotein Cholesterol in Young and Apparently Healthy Women
    Balder, Jan-Willem
    Rimbert, Antoine
    Zhang, Xiang
    Viel, Martijn
    Kanninga, Roan
    van Dijk, Freerk
    Lansberg, Peter
    Sinke, Richard
    Kuivenhoven, Jan Albert
    CIRCULATION, 2018, 137 (08) : 820 - 831
  • [9] CHOLESTEROL-SYNTHESIS INHIBITION REDUCES TOTAL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN RENAL-TRANSPLANT RECIPIENTS
    KASISKE, BL
    TORTORICE, KL
    HEIMDUTHOY, KL
    RAO, KV
    CLINICAL RESEARCH, 1989, 37 (02): : A493 - A493
  • [10] Fenofibrate lowers small low-density lipoprotein with no change in total low-density lipoprotein cholesterol
    Superko, HR
    Madan, S
    Tonnemacher, D
    Chronos, N
    Garrett, B
    Sheehan, D
    Raul, E
    Frohwein, S
    McGrath, K
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 316A - 316A